Call for patient/clinician input open:
Call for patient/clinician input closed:
NOC Status at Filing:
Manufacturer Requested Reimbursement Criteria1:
Treatment of transthyretin amyloid cardiomyopathy in adult patients
Treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Reimburse with clinical criteria and/or conditions
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.